MedTrace Logo

Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy

NCT01379742 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2013-02-13

No results posted yet for this study

Summary

This study will investigate health related quality of life factors in patients undergoing low dose rate prostate brachytherapy. Patients will be randomized to Iodine-125 Thinstrand (for use with 20 g needles) or Rapidstrand (for use with standard 18 g needles). Urinary, bowel, sexual function and bother will be measured by the EPIC questionnaire at various time intervals.

Conditions

Interventions

DEVICE

RapidStrand seeds for use with 18g needle

Rapidstrand seeds are standard size and are used with 20 g needles

DEVICE

ThinStrand

ThinStrand seeds are smaller in diameter and used with 20g needles

Sponsors & Collaborators

  • Prostate Cancer Foundation of Chicago

    lead OTHER

Principal Investigators

  • Brian J Moran, MD · Chicago Prostate Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2013-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01379742 on ClinicalTrials.gov